Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections

dc.contributor.authorDing J.
dc.contributor.authorHoglund R.M.
dc.contributor.authorTagbor H.
dc.contributor.authorTinto H.
dc.contributor.authorValéa I.
dc.contributor.authorMwapasa V.
dc.contributor.authorKalilani-Phiri L.
dc.contributor.authorVan Geertruyden J.P.
dc.contributor.authorNambozi M.
dc.contributor.authorMulenga M.
dc.contributor.authorHachizovu S.
dc.contributor.authorRavinetto R.
dc.contributor.authorD'Alessandro U.
dc.contributor.authorTarning J.
dc.contributor.correspondenceDing J.
dc.contributor.otherMahidol University
dc.date.accessioned2024-09-13T18:26:21Z
dc.date.available2024-09-13T18:26:21Z
dc.date.issued2024-01-01
dc.description.abstractArtemisinin-based combination therapy (ACT) is the first-line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant patient populations. This study aimed to evaluate the PK properties of amodiaquine and its active metabolite, desethylamodiaquine, and piperaquine in women in their second and third trimester of pregnancy with uncomplicated P. falciparum infections. Eligible pregnant women received either artesunate-amodiaquine (200/540 mg daily, n = 771) or dihydroartemisinin-piperaquine (40/960 mg daily, n = 755) for 3 days (NCT00852423). Population PK properties were evaluated using nonlinear mixed-effects modeling, and effect of gestational age and trimester was evaluated as covariates. 1071 amodiaquine and 1087 desethylamodiaquine plasma concentrations, and 976 piperaquine plasma concentrations, were included in the population PK analysis. Amodiaquine concentrations were described accurately with a one-compartment disposition model followed by a two-compartment disposition model of desethylamodiaquine. The relative bioavailability of amodiaquine increased with gestational age (1.25% per week). The predicted exposure to desethylamodiaquine was 2.8%–32.2% higher in pregnant women than that reported in non-pregnant women, while day 7 concentrations were comparable. Piperaquine concentrations were adequately described by a three-compartment disposition model. Neither gestational age nor trimester had significant impact on the PK of piperaquine. The predicted exposure and day 7 concentrations of piperaquine were similar to that reported in non-pregnant women. In conclusion, the exposure to desethylamodiaquine and piperaquine was similar to that in non-pregnant women. Dose adjustment is not warranted for women in their second and their trimester of pregnancy.
dc.identifier.citationCPT: Pharmacometrics and Systems Pharmacology (2024)
dc.identifier.doi10.1002/psp4.13211
dc.identifier.eissn21638306
dc.identifier.scopus2-s2.0-85203188526
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/101194
dc.rights.holderSCOPUS
dc.subjectMathematics
dc.subjectMedicine
dc.titlePopulation pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85203188526&origin=inward
oaire.citation.titleCPT: Pharmacometrics and Systems Pharmacology
oairecerif.author.affiliationWorldWide Antimalarial Resistance Network
oairecerif.author.affiliationKamuzu University of Health Sciences
oairecerif.author.affiliationMahidol Oxford Tropical Medicine Research Unit
oairecerif.author.affiliationUniversity of Health and Allied Sciences, Ghana
oairecerif.author.affiliationTropical Diseases Research Centre Ndola
oairecerif.author.affiliationUniversity of the Western Cape
oairecerif.author.affiliationLondon School of Hygiene & Tropical Medicine
oairecerif.author.affiliationPrins Leopold Instituut voor Tropische Geneeskunde
oairecerif.author.affiliationUniversiteit Antwerpen
oairecerif.author.affiliationNuffield Department of Medicine
oairecerif.author.affiliationClinical Research Unit of Nanoro

Files

Collections